A Thorough QTc Evaluation of the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants: A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel Study With a Nested Crossover Design for Positive Control With Moxifloxacin Administration

This study will investigate the effect of multiple doses of cotadutide on the cardiac activity (QTc interval) of healthy participants.

开始日期2023-01-03

申办/合作机构

AstraZeneca PLC

EUCTR2021-005484-53-GR / Unknown status临床2期

A Phase II Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis - PROXYMO-ADVANCE

开始日期2022-09-09

申办/合作机构

AstraZeneca AB

NCT05517226 / Terminated临床1期

A Phase I, Parallel-group, Multi-center, Open-label, Investigation of the Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Injection of Cotadutide in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Participants With Normal Hepatic Function

This study will assess the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous injection of cotadutide in participants with mild, moderate or severe hepatic impairment compared to participants with normal hepatic function.

开始日期2022-09-06

申办/合作机构

AstraZeneca PLC

[+1]

100 项与 Cotadutide 相关的临床结果

登录后查看更多信息

100 项与 Cotadutide 相关的转化医学

登录后查看更多信息

100 项与 Cotadutide 相关的专利（医药）

登录后查看更多信息

项与 Cotadutide 相关的文献（医药）

2024-03-01·Peptides

Cotadutide (GLP-1/Glucagon dual receptor agonist) modulates hypothalamic orexigenic and anorexigenic neuropeptides in obese mice

Article

作者: Mandarim-de-Lacerda, Carlos A ; Marinho, Thatiany Souza ; Aguila, Marcia Barbosa ; Reis, Thiago Santos ; Spezani, Renata

The hypothalamic neuropeptides linked to appetite and satiety were investigated in obese mice treated with cotadutide (a dual receptor agonist of glucagon-like peptide 1 (GLP-1R)/Glucagon (GCGR)). Twelve-week-old male C57BL/6 mice were fed a control diet (C group, n = 20) or a high-fat diet (HF group, n = 20) for ten weeks. Each group was further divided, adding cotadutide treatment and forming groups C, CC, HF, and HFC for four additional weeks. The hypothalamic arcuate neurons were labeled by immunofluorescence, and protein expressions (Western blotting) for neuropeptide Y (NPY), proopiomelanocortin (POMC), agouti-related protein (AgRP), and cocaine- and amphetamine-regulated transcript (CART). Cotadutide enhanced POMC and CART neuropeptides and depressed NPY and AGRP neuropeptides. In addition, gene expressions (RT-qPCR) determined that Lepr (leptin receptor) and Calcr (calcitonin receptor) were diminished in HF compared to C but enhanced in CC compared to C and HFC compared to HF. Besides, Socs3 (suppressor of cytokine signaling 3) was decreased in HFC compared to HF, while Sst (somatostatin) was higher in HFC compared to HF; Tac1 (tachykinin 1) and Mc4r (melanocortin-4-receptor) were lower in HF compared to C but increased in HFC compared to HF. Also, Glp1r and Gcgr were higher in HFC compared to HF. In conclusion, the findings are compelling, demonstrating the effects of cotadutide on hypothalamic neuropeptides and hormone receptors of obese mice. Cotadutide modulates energy balance through the gut-brain axis and its associated signaling pathways. The study provides insights into the mechanisms underlying cotadutide's anti-obesity effects and its possible implications for obesity treatment.

2024-02-01·Neurogastroenterology and motility

The role of gastric function in control of food intake (and body weight) in relation to obesity, as well as pharmacological and surgical interventions

Review

作者: Camilleri, Michael

Abstract:

Purpose:

The objectives of this review are to summarize the role of gastric motor functions in the development of satiation (defined broadly as postprandial fullness) and satiety (reduced appetite or postponing desire to eat after a meal) and their impact on weight change. The specific topics are the methods of measurement of gastric emptying and accommodation and their impact on food intake, satiation, and satiety. A second focus contrasts bariatric surgery to endoscopic gastroplasty that alter gastric emptying and incretin responses in markedly divergent manners.

Background:

The hormone, GLP‐1, retards gastric emptying and increases gastric accommodation through vagally‐mediated effects. Indeed, these effects provide the basis for the association of altered gastric emptying in the appetite and weight loss responses to pharmacological interventions particularly by those acting on receptors of incretin agonists such as liraglutide and the dual agonists, tirzepatide and cotadutide, all of which retard gastric emptying. In fact, retardation of gastric emptying and gastrointestinal adverse effects have been shown to contribute in part to the weight loss in response to this class of pharmacological agents.

Summary:

The motor functions of the stomach are relevant to postprandial fullness and to interventions aimed at weight loss in people with obesity.

2024-01-01·European journal of pharmacology

OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes

Article

作者: Karsdal, Morten Asser ; Kayed, Ashref ; Melander, Simone Anna ; Andreassen, Kim Vietz ; Henriksen, Kim

OBJECTIVE:

Dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonists are therapeutic agents with an interesting liver-specific mode of action suitable for metabolic complications. In this study, dual GLP-1 and glucagon receptor agonist OXM-104 is compared head-to-head with the once-daily dual GLP-1 and glucagon receptor agonist cotadutide and GLP-1 receptor agonist semaglutide to explore the metabolic efficacy of OXM-104.

METHODS:

The in vitro potencies of OXM-104, cotadutide and semaglutide were assessed using reporter assays. In addition, in vivo efficacy was investigated using mouse models of diet-induced obesity (DIO mice), diabetes (db/db mice) and diet-induced NASH mice (MS-NASH).

RESULTS:

OXM-104 was found to only activate the GLP-1 and glucagon with no cross-reactivity at the (GIP) receptor. Cotadutide was also found to activate the GLP-1 and glucagon receptors, whereas semaglutide only showed activity at the GLP-1 receptor. OXM-104, cotadutide, and semaglutide elicited marked reductions in body weight and improved glucose control. In contrast, hepatoprotective effects, i.e., reductions in steatosis and fibrosis, as well as liver fibrotic biomarkers, were more prominent with OXM-104 and cotadutide than those seen with semaglutide, demonstrated by an improved NAFLD activity score (NAS) by OXM-104 and cotadutide, underlining the importance of the glucagon receptor.

CONCLUSION:

These results show that dual GLP-1 and glucagon receptor agonism is superior to GLP-1 alone. OXM-104 was found to be a promising therapeutic candidate for the treatment of metabolic complications such as obesity, type 2 diabetes and NASH.

项与 Cotadutide 相关的新闻（医药）

2024-04-17

·BioSpace

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the Third Quarter of 2024 First Patient Dosed in the Multiple Ascending Dose Part 2 Expected in the Third Quarter of 2024 CAMBRIDGE, Mass., April 17, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the single ascending dose (SAD) Part 1 of its two-part Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. "Dosing of the first patient in this trial is a groundbreaking achievement in the development of DA-1726, marking the first time this cardiometabolic asset will be tested in humans, bringing it one step closer to treating obesity, utilizing a novel mechanism as compared to other currently available treatments," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "Although the main goal of the SAD part of this study is to assess the safety and tolerability of DA-1726, based on pre-clinical evidence, we believe that it may have a better tolerability pro currently available GLP-1 agonists due to its balanced activation of GLP1R and glucagon receptors, reducing food intake while also increasing energy expenditure. Specifically, in pre-clinical mouse models, DA-1726 showed superior weight loss compared to semaglutide (Wegovy®) and resulted in similar weight reduction while consuming more food compared to tirzepatide (Zepbound™). Notably, we have significantly accelerated the timelines for the Phase 1 trial, and look forward to dosing the first patient in the multiple ascending dose (MAD) Part 2 in the third quarter of this year. Additionally, we now expect to report top-line data from the SAD Part 1 in the third quarter of 2024, and the MAD Part 2 in the first quarter of 2025." The Phase 1 trial is designed to be a randomized, placebo-controlled, double-blind, two-part study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects. The Part 1 SAD study is expected to enroll approximately 45 participants, randomized into one of 5 planned cohorts. Each cohort will be randomized in a 6:3 ratio of DA-1726 or placebo. Part 2 is designed as a MAD study, expected to enroll approximately 36 participants, who will be randomized at the same 6:3 ratio into 4 planned cohorts, each to receive 4 weekly administrations of DA-1726 or placebo. The primary endpoint will assess the safety and tolerability of DA-1726 by monitoring adverse events (AEs), serious adverse events (SAEs), treatment emergent adverse events (TEAEs) and AEs leading to treatment discontinuation. Secondary endpoints include the PK of DA-1726, assessed via serum concentrations over time and metabolite profiling at the highest doses of DA-1726. Exploratory endpoints will include the effect of DA-1726 on metabolic parameters, cardiac parameters, fasting lipid levels, body weight, waist circumference and body mass index (BMI), among others. For more information on this clinical trial, please visit: NCT06252220. About DA-1726 DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and MASH that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in preclinical mice models, resulted in improved weight loss compared to semaglutide and cotadutide (another OXM analogue). About NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. For more information, please visit . Forward Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "intends", "projects," "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with NeuroBo's ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of NeuroBo's current and future product candidates, the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of NeuroBo; the cooperation of NeuroBo's contract manufacturers, clinical study partners and others involved in the development of NeuroBo's current and future product candidates; potential negative interactions between NeuroBo's product candidates and any other products with which they are combined for treatment; NeuroBo's ability to initiate and complete clinical trials on a timely basis; our ability to recruit subjects for its clinical trials; whether NeuroBo receives results from NeuroBo's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to NeuroBo's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. NeuroBo does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contacts: NeuroBo Pharmaceuticals Marshall H. Woodworth Chief Financial Officer +1-857-299-1033 marshall.woodworth@neurobopharma.com Rx Communications Group Michael Miller +1-917-633-6086 mmiller@rxir.com Company Codes: NASDAQ-NMS:NRBO

临床1期临床结果

2024-03-14

·Firstwordpharma

Madrigal's Rezdiffra clinches first FDA approval for MASH

After years of clinical failures and FDA rejections in the liver disease space, Madrigal Pharmaceuticals has finally taken gold in the race for the first approval in metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). Specifically, the FDA granted Rezdiffra (resmetirom) accelerated approval to treat adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis consistent with stages F2 to F3 fibrosis, in conjunction with diet and exercise. A biopsy is not required for diagnosis.The THR-β selective agonist will be available to US patients starting April, after months of building excitement. In a 70-physician FirstWord poll conducted last month, 30% of respondents said they were very enthusiastic about prescribing the drug (see: Physician Views Results: Potential new NASH drug gets positive assessment from US docs).This greenlight will most likely open the MASH floodgates. Despite the difficulty designing drugs for the heterogeneous liver disease, which has a variety of etiologies and paths of progression, a series of promising candidates across multiple mechanisms have lined up behind Rezdiffra, such as FGF21 analogues and GLP-1 agonists. For more on the development landscape, see Spotlight On: MASH pipeline holds promise of multiple mechanisms for disease management.Rezdiffra’s approval comes, in part, because it was able to demonstrate efficacy without the safety concerns that sunk Intercept Pharmaceuticals’ obeticholic acid. Treatment defining dataRezdiffra, a once-daily, oral candidate secured FDA approval on Thursday thanks to 52-week data from the pivotal MAESTRO-NASH study, which met the co-primary endpoints of MASH resolution with no worsening of fibrosis, and at least a one-stage reduction in fibrosis with no worsening of non-alcoholic fatty liver disease (NAFLD) activity score. According to results, 25.9% of patients who received the 80mg dose, and 29.9% in the 100mg arm, achieved MASH resolution endpoint, compared with 9.7% for placebo. For fibrosis improvement, the rates were 24.2% and 25.9% for the low- and high-dose arms, respectively, versus 14.2% for placebo.Most of the reported side effects were mild-to-moderate, with a roughly 11-13% serious adverse event rate across each of the three cohorts. There was no incidence of drug-induced liver injury, increases in bone fractures or adverse events linked to thyroid hormone effects outside the liver such as heart rate changes.Rezdiffra’s label reflects the clinical safety results. The drug does not carry a boxed warning, and its label notes that the most common side effects are diarrhoea, nausea, pruritus, vomiting, constipation, abdominal pain, and dizziness.First success of many failuresMadrigal’s journey to FDA approval comes after the failures of several other drug developers to show both safety and efficacy of their MASH programmes, most notably that of obethicholic acid from Intercept.The biotech received its first complete response letter for the candidate in 2020, which said that the predicted benefit of obethicholic acid "does not sufficiently outweigh the potential risks.” Three years later, FDA again rejected the treatment, saying that approval would require, at a minimum, the successful completion of a long-term outcomes Phase III trial.Large pharmas have also seen their fair share of setbacks in the disease. Last year, Novartis ended a partnership with Pliant Therapeutics to develop the latter's integrin αVβ1 inhibitor PLN-1474 for MASH.Pfizer and AstraZeneca have both recently trimmed their MASH pipelines. The UK drugmaker terminated development of late-stage injectable GLP-1/glucagon co-agonist cotadutide last year, while the US pharma has ended at least two MASH programmes in the last three years: ketohexokinase inhibitor PF-06835919, and oral GLP-1 receptor agonist danuglipron. MASH future looks brightNow that Madrigal has shown approval is possible, drugmakers waiting in the wings may be more bullish on the prospects for their own programmes. FirstWord spoke with 89bio chief medical officer Hank Mansbach earlier this week on the chances of accelerated approval for FGF21 analogue pegozafermin, for which it just launched a Phase III trial. At the time, Mansbach said an approval for resmetirom would give the company a confidence boost. Other companies who have shared promising mid-stage data include fellow FGF21 developer Akero Therapeutics, Ionis Pharmaceuticals’ antisense inhibitor, Sagimet Biosciences and its fatty acid synthase (FASN) inhibitor, partners Boehringer Ingelheim and Zealand Pharma for their dual GLP-1 and glucagon agonist, as well as Viking Therapeutics, whose candidate has the same mechanism of action as Madrigal’s.

上市批准临床3期加速审批临床结果

2024-02-29

·PRNewswire

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

First Patient Expected to be Randomized in the Second Quarter of 2024 CAMBRIDGE, Mass., Feb. 29, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has received first site Institutional Review Board (IRB) approval for Alexander Prezioso, M.D., Investigator, Clinical Pharmacology of Miami, in Hialeah, FL, to proceed with the Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. The company expects to randomize the first patient in the second quarter of this year. "With this first site IRB approval, we have achieved another significant milestone in the development of DA-1726, bringing the program one step closer to the clinic," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "This promising cardiometabolic asset may have a better tolerability profile than currently available GLP-1 agonists due to its balanced activation of GLP1R and glucagon receptors. As previously reported, in mouse models, DA-1726 showed superior weight loss compared to semaglutide (Wegovy®), and its administration resulted in similar weight reduction while consuming more food compared to tirzepatide (Zepbound™). We look forward to working closely with our contract research organization (CRO) partner and our investigators, such as Dr. Prezioso, to start randomizing patients in the second quarter of this year. We expect to report top-line data from the single ascending dose (SAD) Part 1 in the first half of 2025 and the multiple ascending dose (MAD) Part 2 in the second half of 2025." The Phase 1 trial is designed to be a randomized, placebo-controlled, double-blind, two-part study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects. Part 1 will be a single ascending dose (SAD) study, expected to enroll approximately 45 participants, randomized into one of 5 planned cohorts. Each cohort will be randomized in a 6:3 ratio of DA-1726 or placebo. Part 2 will be a multiple ascending dose (MAD) study, expected to enroll approximately 36 participants, who will be randomized at the same 6:3 ratio into 4 planned cohorts, each to receive 4 weekly administrations of DA-1726 or placebo. The primary endpoint will assess the safety and tolerability of DA-1726 by monitoring adverse events (AEs), serious adverse events (SAEs), treatment emergent adverse events (TEAEs) and AEs leading to treatment discontinuation. Secondary endpoints include the PK of DA-1726, assessed via serum concentrations over time and metabolite profiling at the highest doses of DA-1726. Exploratory endpoints will include the effect of DA-1726 on metabolic parameters, cardiac parameters, fasting lipid levels, body weight, waist circumference and body mass index (BMI), among others. For more information on this clinical trial, please visit: NCT06252220. About DA-1726 DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and NASH that is to be administered once weekly subcutaneously. DA-1726 as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in preclinical mice models, resulted in improved weight loss compared to semaglutide and cotadutide (another OXM analogue). About NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. For more information, please visit . Forward Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "intends", "projects," "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with NeuroBo's ability to execute on its commercial strategy; the timeline for regulatory submissions; ability to obtain regulatory approval through the development steps of NeuroBo's current and future product candidates, the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of NeuroBo; the cooperation of our contract manufacturers, clinical study partners and others involved in the development of NeuroBo's current and future product candidates; potential negative interactions between our product candidates and any other products with which they are combined for treatment; NeuroBo's ability to initiate and complete clinical trials on a timely basis; our ability to recruit subjects for its clinical trials; whether NeuroBo receives results from NeuroBo's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; effects of changes in applicable laws or regulations; effects of changes to NeuroBo's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. NeuroBo does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contacts: NeuroBo Pharmaceuticals Marshall H. Woodworth Interim Chief Financial Officer +1-857-299-1033 [email protected] Rx Communications Group Michael Miller +1-917-633-6086 [email protected] SOURCE NeuroBo Pharmaceuticals, Inc.

临床1期

100 项与 Cotadutide 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11304	-	-	DB15194

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
纤维化	临床3期	美国	AstraZeneca AB	2022-07-12
纤维化	临床3期	美国	阿斯利康全球研发（中国）有限公司	2022-07-12
纤维化	临床3期	日本	阿斯利康全球研发（中国）有限公司	2022-07-12
纤维化	临床3期	日本	AstraZeneca AB	2022-07-12
纤维化	临床3期	阿根廷	AstraZeneca AB	2022-07-12
纤维化	临床3期	阿根廷	阿斯利康全球研发（中国）有限公司	2022-07-12
纤维化	临床3期	澳大利亚	AstraZeneca AB	2022-07-12
纤维化	临床3期	澳大利亚	阿斯利康全球研发（中国）有限公司	2022-07-12
纤维化	临床3期	奥地利	阿斯利康全球研发（中国）有限公司	2022-07-12
纤维化	临床3期	奥地利	AstraZeneca AB	2022-07-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04515849 (EASD2023)	临床2期	糖尿病肾病	-	Cotadutide 100 µg	網壓網選膚觸遞膚網憲(蓋鏇觸繭淵醖夢範願憲) = 窪鏇醖鏇蓋膚淵淵鹹構窪鏇鹹憲構積齋構淵襯 (廠醖糧淵觸糧鑰鏇醖淵, -52.5 ~ -23.9) 更多	积极	2023-10-03
				Cotadutide 300 µg	獵顧鬱鹽築淵顧廠齋觸(築襯願餘積繭獵觸遞積) = 糧鹹遞淵夢遞糧窪遞選簾製選鏇網範積鏇構鹽 (齋窪鑰膚遞醖壓蓋艱簾 ) 更多
ERA2023	临床2期	慢性肾病	248	Cotadutide	鑰鑰觸構顧窪淵獵獵壓(齋鏇鹽鹹齋襯觸鑰衊壓) = 選鏇夢醖夢鏇夢夢膚壓觸鏇鏇鑰廠壓膚獵顧鏇 (構糧製顧壓膚獵獵餘餘, -52,5, ~ 23.9) 更多	-	2023-06-15
NAASO2022	临床2期	肥胖	18	Cotadutide	憲鹽鹹範壓鑰衊膚餘廠(獵積簾夢艱窪衊製築願) = 憲廠鑰獵淵蓋築壓襯鹽網鬱襯衊糧鬱憲構選製 (鏇鹹淵鹹鹽餘鹹鑰壓憲 ) 更多	-	2022-11-21
				Placebo	憲鹽鹹範壓鑰衊膚餘廠(獵積簾夢艱窪衊製築願) = 淵憲製餘鹽夢壓壓鏇積網鬱襯衊糧鬱憲構選製 (鏇鹹淵鹹鹽餘鹹鑰壓憲 ) 更多
NCT03550378 (Pubmed) 人工标引	临床2期	2型糖尿病 \| 慢性肾病	41	Cotadutide	鹹鑰窪艱窪憲鏇糧廠壓(夢餘衊蓋醖蓋壓鏇繭製) = 壓醖衊築餘醖憲襯網積願廠憲簾窪膚淵艱襯齋 (壓夢鏇壓壓遞鏇鹹鑰選 ) 更多	积极	2022-04-11
				Placebo	鹹鑰窪艱窪憲鏇糧廠壓(夢餘衊蓋醖蓋壓鏇繭製) = 觸衊糧築糧築願淵願壓願廠憲簾窪膚淵艱襯齋 (壓夢鏇壓壓遞鏇鹹鑰選 ) 更多
NCT03444584 (EASD2021)	临床2期	2型糖尿病追加	49	Cotadutide+Dapagliflozin+Metformin	鹽廠淵簾網廠製觸廠鑰(顧淵鬱廠齋積築製廠積) = 衊餘襯憲夢獵廠艱糧製鑰鑰獵窪獵廠憲夢齋窪 (網鬱淵顧鬱繭窪蓋齋觸 ) 更多	积极	2021-09-30
NCT03645421 (Pubmed) 人工标引	临床1/2期	2型糖尿病 \| 超重 \| 肥胖	61	cotadutide	醖觸選夢網繭鬱齋膚積(積顧襯選觸觸鹽製積鏇) = no serious adverse events. 衊齋艱衊鏇遞壓鹹積淵 (獵廠襯餘積鑰選觸鹹構 ) 更多	积极	2021-08-01
				Placebo
ADA2021	N/A	2型糖尿病肥胖	-	Cotadutide	築壓醖鏇齋壓餘範鏇窪(築獵廠積構夢壓夢衊膚) = 淵築築糧醖願憲衊衊糧淵製夢鹽鑰艱憲鑰蓋膚 (遞鑰築鹹齋壓築襯選顧, -4.85%, ~ 3.10%) 更多	-	2021-06-01
				Placebo	築壓醖鏇齋壓餘範鏇窪(築獵廠積構夢壓夢衊膚) = 壓鹽窪夢網鬱醖鬱鑰膚淵製夢鹽鑰艱憲鑰蓋膚 (遞鑰築鹹齋壓築襯選顧, -2.66%, ~ 0.13%) 更多
ADA2021	N/A	2型糖尿病 \| 糖尿病肾病	41	Cotadutide	窪選獵網蓋顧網獵鏇蓋(鹽簾淵鑰顧鹽築獵糧壓) = 繭範齋遞蓋齋鏇鏇壓鹽窪積鹽積簾製鬱糧繭遞 (壓鏇鏇艱蓋膚鏇憲齋糧 ) 更多	-	2021-06-01
				Placebo	願遞艱積繭獵觸鬱窪壓(淵夢觸壓繭窪願淵壓壓) = 網襯鏇網夢選艱鹽蓋範築蓋鹽繭醖鏇淵鹹願鬱 (遞夢蓋鬱餘餘窪衊築網 )
NCT03596177 (CTgov)	临床2期	2型糖尿病 \| 肥胖	28	Placebo (Placebo)	壓繭憲鬱獵憲選艱夢鑰(廠願範齋夢淵餘廠衊窪) = 壓鹹壓製製醖齋獵鏇鏇鑰鹹顧願選艱蓋顧積積 (製壓夢襯廠膚鹽夢遞鹹, 範繭製淵簾夢選艱觸簾 ~ 夢齋鬱網憲繭願膚鑰製) 更多	-	2021-01-15
				Placebo+MEDI0382 (MEDI0382)	壓繭憲鬱獵憲選艱夢鑰(廠願範齋夢淵餘廠衊窪) = 壓網積夢鑰獵膚構積鬱鑰鹹顧願選艱蓋顧積積 (製壓夢襯廠膚鹽夢遞鹹, 遞蓋淵鬱鏇範壓築餘艱 ~ 製壓簾鏇壓顧範廠鹹獵) 更多
NCT03235050 (CTgov)	临床2期	2型糖尿病 \| 肥胖	834	Placebo+Metformin (Placebo)	餘選壓襯顧選繭襯鏇簾(壓選鬱壓窪壓觸夢築糧) = 積糧簾蓋網鬱顧壓選糧襯鹽顧選獵齋糧構廠鑰 (淵窪襯構膚齋鹽醖衊願, 範夢膚觸淵壓窪糧鏇淵 ~ 窪獵糧鹹淵夢範繭壓齋) 更多	-	2020-07-20
				MEDI0382+Metformin (MEDI0382 100 mcg)	餘選壓襯顧選繭襯鏇簾(壓選鬱壓窪壓觸夢築糧) = 憲遞艱鑰獵鑰選鏇憲夢襯鹽顧選獵齋糧構廠鑰 (淵窪襯構膚齋鹽醖衊願, 願壓鬱夢艱構廠願願築 ~ 淵築艱醖願鑰簾積淵築) 更多